Related Experiment Video
Updated: Jul 1, 2026
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Frequent exposure to biologics is associated with small intestinal bacterial overgrowth in patients with Crohn's
Yuanyi Zhao1, Hui Tao2, Zhao Yang2
1Department of Gastroenterology and Hepatology, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
Background:
Small intestinal bacterial overgrowth (SIBO) is characterized by excessive bacteria in the small intestine, often accompanied by gastrointestinal symptoms. The advent of biologic therapies has significantly advanced the treatment of Crohn's disease (CD), yet their influence on the development of SIBO remains unclear.
Aims:
This study aims to elucidate the relationship between exposure to biologic therapies and the incidence of SIBO in CD patients.
Methods:
This retrospective case-control study enrolled CD patients who underwent lactulose hydrogen-methane breath test (LHMBT) at Jinling Hospital from 2021 to 2024. Clinical data were collected and the risk factors for SIBO were identified using both univariate and multivariate logistic regression. Additionally, model validation was carried out using receiver operating characteristic (ROC) curve analysis, confusion matrix and 5-fold cross-validation.
Results:
(1) Among the 86 CD patients enrolled, biologic administration differed significantly between the SIBO-positive (n = 43) and SIBO-negative (n = 43) group. (2) Identified risk factors for SIBO in CD patients included use of biologics in excess of five times compared to those with no biologic exposure (OR = 4.541, P = 0.033), and intestinal stenosis (OR = 3.262, P = 0.034). (3) ROC curve analysis was performed to evaluate the predictive value of the combined model that included biologic exposure frequency (≥5 times), body mass index (BMI), current steroid use, disease duration and intestinal stenosis, for predicting SIBO in CD patients (AUC = 0.778, P < 0.001). (4) The confusion matrix demonstrated an accuracy of 70.9% and a precision of 67.3%, while the 5-fold cross-validation verified that the predictive model achieved a mean AUC of 0.779 ± 0.03.
Conclusions:
This study indicated that frequent exposure to biologics is associated with an increased presence of SIBO in CD patients, particularly in those with intestinal strictures.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:18Dysbiosis of the Gut Microbiota
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents